Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5‐ASA use

Conflicting data exist about proteinuria in inflammatory bowel diseases. It is still unclear whether the occurrence of proteinuria in inflammatory bowel disease patients is an extra‐intestinal manifestation of disease or the result of adverse effects to medication, especially to aminosalicylates (ASA).

[1]  B. Sands,et al.  Therapy of inflammatory bowel disease. , 2000, Gastroenterology.

[2]  E. Vasiliauskas,et al.  Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease. , 1999, Gastroenterology.

[3]  A. Gutzeit,et al.  Increased production of vascular endothelial growth factor by peripheral blood mononuclear cells in patients with inflammatory bowel disease. , 1999, European journal of gastroenterology & hepatology.

[4]  J. Cabezuelo,et al.  Crohn’s Disease with Amyloid A Amyloidosis and Nephrotic Syndrome , 1999, Nephron.

[5]  T. Happ,et al.  Glomerular and tubular proteinuria as markers of nephropathy in rheumatoid arthritis. , 1999, Rheumatology.

[6]  P. Stevens,et al.  Late onset interstitial nephritis associated with mesalazine treatment , 1998, BMJ.

[7]  X. Causse,et al.  [Chronic renal insufficiency (interstitial nephritis) under mesalazine]. , 1998, Gastroenterologie clinique et biologique.

[8]  R. Dhiman,et al.  Membranous glomerulonephritis in association with ulcerative colitis. , 1998, Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology.

[9]  E. Losada,et al.  Mesalazine-associated tubulo-interstitial nephritis in inflammatory bowel disease. , 1998, Clinical nephrology.

[10]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[11]  W. Kruis,et al.  Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate. , 1997, Gut.

[12]  B. Schumacher,et al.  Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis. , 1997, Hepato-gastroenterology.

[13]  S. Targan,et al.  A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. , 1997, The New England journal of medicine.

[14]  J. Schölmerich,et al.  [Nephrotic syndrome as the initial symptom of Crohn disease]. , 1996, Zeitschrift fur Gastroenterologie.

[15]  W. Kreisel,et al.  Renal tubular damage: an extraintestinal manifestation of chronic inflammatory bowel disease. , 1996, European journal of gastroenterology & hepatology.

[16]  D. Kelleher,et al.  Microalbuminuria correlates with intestinal histopathological grading in patients with inflammatory bowel disease. , 1996, Gut.

[17]  P. Keeling,et al.  Microalbuminuria in inflammatory bowel disease. , 1994, Gut.

[18]  P. Thuluvath,et al.  Mesalazine induced interstitial nephritis. , 1994, Gut.

[19]  N. Klein,et al.  Disruption of sulphated glycosaminoglycans in intestinal inflammation , 1993, The Lancet.

[20]  R. Heyderman,et al.  Alteration in glycosaminoglycan metabolism and surface charge on human umbilical vein endothelial cells induced by cytokines, endotoxin and neutrophils. , 1992, Journal of cell science.

[21]  J. Schölmerich,et al.  Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. , 1992, Gastroenterology.

[22]  N. Tsuji,et al.  Serum tumor necrosis factor activity in inflammatory bowel disease. , 1992, Immunopharmacology and immunotoxicology.

[23]  A. Morley,et al.  Nephrotic syndrome in ulcerative colitis. , 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[24]  K. Bilyard,et al.  Mesalazine: an overview of key preclinical studies. , 1990, Scandinavian journal of gastroenterology. Supplement.

[25]  W. Guder,et al.  A Diagnostic Programme for Quantitative Analysis of Proteinuria , 1989, Journal of clinical chemistry and clinical biochemistry. Zeitschrift fur klinische Chemie und klinische Biochemie.

[26]  J. Bernheim,et al.  Nephrotic syndrome after treatment with 5-aminosalicylic acid , 1988, British medical journal.

[27]  M. Glassman,et al.  Immune-complex glomerulonephritis in Crohn's disease. , 1986, Journal of pediatric gastroenterology and nutrition.

[28]  Boesken Wh.  Diagnostic significance of SDS-PAA-electrophoresis of urinary proteins: different forms of proteinuria and their correlation to renal diseases. , 1979 .

[29]  W. Boesken.  Diagnostic significance of SDS-PAA-electrophoresis of urinary proteins: different forms of proteinuria and their correlation to renal diseases. , 1979, Current problems in clinical biochemistry.

[30]  F Kern,et al.  Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. , 1976, Gastroenterology.

[31]  J. Spencer,et al.  The treatment of ulcerative colitis. , 1962, The American journal of gastroenterology.

[32]  S. Truelove,et al.  Cortisone in ulcerative colitis; final report on a therapeutic trial. , 1955, British medical journal.

[33]  Truelove Sc,et al.  Cortisone in ulcerative colitis; preliminary report on a therapeutic trial. , 1954 .

[34]  S. Truelove,et al.  Cortisone in Ulcerative Colitis , 1954 .